Tissue & Cell Technologies

Founded in 2011, and with facilities in the UK, France and the UAE, Tissue & Cell Technologies Ltd is a medical technology company with clinically specialised products and services for the manipulation and storage of autologous human tissue and stem cells, focussed on regenerative medicine. In 2020, the company launched its Regenerys™ product lines for reconstructive and aesthetic surgery in the United Kingdom, Europe, and the United Arab Emirates. Tissue & Cell Technologies’ product catalogue is based on the Adiposet™ platform, which allows users to transport, process, freeze, store, and retrieve high-viability adipose tissue and stem cells for reconstructive procedures, regenerative medicine therapies and procedures that eliminates the current inefficient and wasteful need to use harvested fat and cells in the same procedure on the same day, and allows procedures and methods to be ‘restructured’, ‘deferred’ or ‘staged’ across multiple, more efficient procedures reducing operating theatre usage and the need for general anaesthetic, reducing healthcare costs, reducing post-op complications, and improving patient experience and outcomes. Regenerys™ is a range of injectable, autologous fat grafting products that can be used in high-volume reconstructive procedures (such as post-mastectomy breast reconstruction) and in lower volume cosmetic/aesthetic procedures (including smaller augmentations and as an alternative to cosmetic facial fillers) as well as regenerative medicine therapies based on extracted stem cells, stromal vascular fraction, healing/growth factors and exosome. Tissue & Cell Technologies also has a range of fully approved, autologous cultured cell and stem cell products in development which will provide clinicians with autologous cultured injectables of up to 100 million cultured stem cells for applications including skin, hair regrowth, orthopedics, and rejuvenation. Tissue & Cell Technologies’ MHRA approved legacy products include autologous and allogeneic cultured skin graft products: MySkin™ and CryoSkin™ for treatment of serious and life-threatening burns and wound healing. As at the end of 2021, the company's services have been used in more than 30 clinics and hospitals in the UK and Europe, for performing large volume breast reconstruction for women who underwent mastectomies due to breast cancer, cosmetic treatments, and reconstruction and plastic surgery for trauma and patients who have suffered severe burns. The company has substantial existing NHS and European contracts, high profile commercial relationships, and has a number of large-scale funded studies and collaborations including Guys & St Thomas’s Hospital, the Belfast City Hospital, Nottingham University Hospital, Prof. Gino Rigotti (Verona & Brescia), the Sorbonne University Hospitals (AP-HP Paris), Hospital Sta Creu & St Pau (Barcelona), University Hospital of Brussels, University Hospital of Amsterdam, the Medizinische HochSchule Hannover, and the Institut Gustav Roussy (Paris).

1. Series A

   Jun 10, 2019

   Amount

   $0.6M

   Investors

   Locked